GlassScriptPhysician profile
Stanley C Shadid
NPI 1386904183
$362,902.00
in general payments reported to CMS, 2019-2025
55 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $72K · 2021: $55K · 2022: $67K · 2023: $64K · 2024: $41K · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Travel and Lodging: $16K · Food and Beverage: $5,542 · Consulting Fee: $3,469 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,575.00 |
| Travel and Lodging | $15,713.31 |
| Food and Beverage | $5,542.04 |
| Consulting Fee | $3,468.75 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $347,722.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Eli Lilly and Company | $5,259.96 | 2023 | |
| Genentech USA, INC. | $2,712.80 | 2020-2022 | |
| Abbvie INC. | $779.41 | 2019-2025 | Ubrelvy, Botox, Qulipta |
| Pfizer INC. | $596.11 | 2019-2025 | |
| Amgen INC. | $510.91 | 2019-2024 | Repatha, Otezla |
| Si-Bone, INC. | $469.67 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.76 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $417.75 | 2019-2024 | Airsupra, Breztri, Fasenra |
| Organogenesis INC. | $407.58 | 2021-2024 | Puraply Wound Matrix, Puraply, Matrix |
| Novo Nordisk INC | $378.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $373.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $213.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $183.83 | 2022-2025 | Freestyle Libre 3 |
| Tris Pharma INC | $177.39 | 2023-2025 | Dyanavel Xr |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $169.13 | 2024-2025 | Korlym |
| Collegium Pharmaceutical, INC. | $163.52 | 2025 | Jornay Pm |
| Lundbeck LLC | $160.29 | 2024-2025 | Vyepti |
| Grt US Holding, INC. | $154.58 | 2022 | |
| Ibsa Pharma INC. | $141.20 | 2025 | Flector, Licart, Tirosint |
| Exact Sciences Corporation | $116.47 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $105.90 | 2021-2022 | |
| Corium, LLC | $93.38 | 2022-2023 | Azstarys |
| Antares Pharma, INC. | $88.19 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Janssen Pharmaceuticals, INC | $81.27 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $79.64 | 2019-2024 | Ajovy |
| Astellas Pharma US INC | $77.31 | 2023-2025 | Veozah |
| Noven Therapeutics, LLC | $71.92 | 2025 | Xelstrym, Secuado |
| Allergan, INC. | $55.79 | 2021-2022 | |
| Axsome Therapeutics, INC. | $52.09 | 2025 | Symbravo |
| Sanofi-Aventis U.S. LLC | $51.37 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $48.80 | 2019-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Shire North American Group INC | $44.12 | 2019 | |
| Upsher-Smith Laboratories LLC | $40.59 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $39.19 | 2019 | |
| Idorsia Pharmaceuticals US INC | $36.50 | 2023 | Quviviq |
| Avion Pharmaceuticals | $35.47 | 2023 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $33.47 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $33.33 | 2022-2024 | Qelbree |
| Nevro Corp. | $28.39 | 2023 | Senza |
| Seqirus USA INC | $22.99 | 2025 | Fluad, Flucelvax |
| Neos Therapeutics, LP | $22.62 | 2024 | Adzenys Xr-Odt |
| Daiichi Sankyo INC. | $22.56 | 2025 | Injectafer |
| Medtronic, INC. | $19.57 | 2025 | Intellis Adaptivestim |
| Scynexis, INC. | $18.62 | 2022 | |
| Cequr Corporation | $17.41 | 2025 | Cequr Simplicity |
| Eisai INC. | $16.44 | 2025 | |
| Amarin Pharma, INC. | $15.46 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.01 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $13.80 | 2022 | |
| Esperion Therapeutics, INC. | $13.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.54 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.43 | 2021 | |
| Horizon Therapeutics Plc | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Shadid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.